• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    PMGC Holdings Inc. [Nasdaq: ELAB] Congratulates General Enterprise Ventures, Inc. [NYSE: CITR] on Its Uplisting to the NYSE American, Highlights Equity Stake

    12/4/25 10:57:59 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ELAB alert in real time by email

    NEWPORT BEACH, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC" or the "Company"), and its operating investment division, PMGC Capital LLC ("PMGC Capital"), congratulates General Enterprise Ventures, Inc. (NYSE:CITR) on its uplisting to the NYSE American.

    PMGC Holdings Inc., through its wholly owned subsidiary, PMGC Capital, is an investor in General Enterprise Ventures ("GEVI"). PMGC believes GEVI's uplisting represents a significant corporate milestone that enhances GEVI's visibility and access to institutional capital as it continues scaling its environmentally safe CitroTech fire-prevention technologies.

    Fire Prevention Market

    The global fire prevention and suppression industry is a large and expanding market with increasing demand for safer, environmentally sustainable, and high-performance technologies.

    Growth is driven by:

    • Rising industrial and commercial infrastructure complexity
    • Stricter global regulations banning or limiting PFAS-based firefighting chemicals
    • Greater wildfire frequency and severity
    • Increased safety standards in energy storage, transport, and defense sectors

    The CitroTech family of products, is strategically positioned to benefit from this market expansion by providing non-toxic, environmentally safe, rapidly deployable fire-inhibition solutions.

    CitroTech® Key Safety & Performance Statistics

    The CitroTech technology—is supported by extensive research, patents, and third-party environmental certifications.

    EPA Safer Choice Certification

    CitroTech is recognized under the U.S. Environmental Protection Agency's Safer Choice program, ensuring it meets stringent criteria for human and environmental safety. It is the only fire inhibitor that has received the EPA Safer Choice designation and is recognized as UL GreenGuard Gold.

    Core Product Metrics

    • Lowest Toxins and VOCs

      UL GreenGuard Gold certified safe for VOCs and designated as an EPA Safer Choice formula
    • 80+ Global Patents & Patents Filed or Pending

      Proprietary fire-inhibition technology protected internationally
    • 18+ Environmental Accreditations

      Includes regulatory approvals, independent lab validations, and safety certifications
    • 100% New Construction Lumber Treatable

      CitroTech® can be applied to all new construction lumber for residential, commercial, and industrial building projects

    The company is targeting multiple high-value markets, including:

    • Commercial & industrial fire protection
    • Lumber treatment and building materials
    • Energy storage systems (ESS)
    • Transportation and logistics
    • Military and defense applications
    • Wildfire mitigation and perimeter protection

    Strategic Alignment With PMGC Capital

    PMGC Capital's investment in GEVI underscores the Company's commitment to financing innovation in essential industries with substantial global growth potential. GEVI's uplisting to the NYSE American reflects the strength of its vision, governance, and technology platform, and aligns directly with PMGC Capital's strategy of supporting companies developing safe, sustainable solutions to critical challenges. As the fire-prevention market continues to expand and modernize, PMGC Capital believes that GEVI and its CitroTech® technology are positioned for meaningful long-term growth and value creation.

    About General Enterprise Ventures, Inc.

    General Enterprise Ventures, Inc. is the owner of the CitroTech family of innovative, environmentally safe fire prevention solutions for homes, wood products, and wildfire prevention and asset protection. CitroTech is the only long-term fire inhibitor recognized by the EPA Safer Choice program and tested to UL Greenguard Gold standards, providing effective and scientifically validated wildfire mitigation while safeguarding human and environmental health. The company's growing patent portfolio, recurring-revenue model, and scalable approach support its long-term growth and market expansion. For more information, visit www.citrotech.com.

    About PMGC Capital LLC

    A multi-strategy investment firm focused on direct investments, strategic lending, and acquiring undervalued companies and assets across diverse markets. Our mission is to identify and seize high-potential opportunities, delivering sustainable growth and maximizing returns on capital.

    About PMGC Holdings Inc.

    PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit https://www.pmgcholdings.com.

    Forward-Looking Statements

    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "believes," "expects," "plans," "potential," "would" and "future" or similar expressions such as "look forward" are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in PMGC's filings with the United States Securities and Exchange Commission ("SEC"), including the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 28, 2025, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

    IR Contact:

    [email protected]



    Primary Logo

    Get the next $ELAB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELAB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ELAB
    SEC Filings

    View All

    PMGC Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - PMGC Holdings Inc. (0001840563) (Filer)

    12/10/25 4:01:25 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by PMGC Holdings Inc.

    EFFECT - PMGC Holdings Inc. (0001840563) (Filer)

    12/2/25 12:15:21 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by PMGC Holdings Inc.

    EFFECT - PMGC Holdings Inc. (0001840563) (Filer)

    12/2/25 12:15:08 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PMGC Holdings Inc. [Nasdaq: ELAB] Congratulates General Enterprise Ventures, Inc. [NYSE: CITR] on Its Uplisting to the NYSE American, Highlights Equity Stake

    NEWPORT BEACH, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC" or the "Company"), and its operating investment division, PMGC Capital LLC ("PMGC Capital"), congratulates General Enterprise Ventures, Inc. (NYSE:CITR) on its uplisting to the NYSE American. PMGC Holdings Inc., through its wholly owned subsidiary, PMGC Capital, is an investor in General Enterprise Ventures ("GEVI"). PMGC believes GEVI's uplisting represents a significant corporate milestone that enhances GEVI's visibility and access to institutional capital as it continues scaling its environmentally safe CitroTech fire-prevention technologies. Fire Prevention Market The global fire preven

    12/4/25 10:57:59 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMGC Holdings Inc. Announces AGA Precision Systems LLC's ITAR (International Traffic in Arms Regulations) Registration Approval

    NEWPORT BEACH, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:PMGC) ("PMGC" or the "Company"), a diversified public holding company executing a targeted roll-up strategy in U.S.-based manufacturing, is pleased to announce that its wholly owned subsidiary, AGA Precision Systems LLC ("AGA Precision Systems" or "AGA"), has completed International Traffic in Arms Regulations (ITAR) registration and is in compliance with ITAR. The ITAR is administered by the U.S. State Department's Directorate of Defense Trade Controls, which controls the export and import of defense articles and services. The ITAR registration further enables AGA to pursue defense and aerospace programs

    10/30/25 8:00:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMGC Holdings Inc.'s Subsidiary, AGA Precision Systems LLC, Completes Acquisition of Indarg Engineering, Inc. Expanding Aerospace and Defense Manufacturing Platform

    Strategic Acquisition Accelerates PMGC's U.S. Manufacturing Roll-Up, Expanding Footprint Across Aerospace and Industrial Supply ChainsAcquisition Adds Profitable CNC Platform with Established Customer Relationships to drive earnings scalability and operational synergies NEWPORT BEACH, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:PMGC) ("PMGC" or the "Company"), a diversified public holding company executing a targeted roll-up strategy in U.S.-based manufacturing, today announced that its wholly owned subsidiary, AGA Precision Systems LLC ("AGA"), has acquired all operating assets of Indarg Engineering, Inc., a precision computer numerical control ("CNC") machining

    10/28/25 8:00:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO & CFO Bensler Graydon was granted 3,036,437 units of Series B Preferred Stock (SEC Form 4)

    4 - PMGC Holdings Inc. (0001840563) (Issuer)

    3/28/25 9:52:32 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: New insider Bensler Graydon claimed ownership of 983,120 shares (SEC Form 3)

    3/A - PMGC Holdings Inc. (0001840563) (Issuer)

    3/28/25 9:51:28 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Braeden Lichti was granted 3,336,437 units of Series B Preferred Stock (SEC Form 4)

    4 - PMGC Holdings Inc. (0001840563) (Issuer)

    3/28/25 9:47:45 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAB
    Leadership Updates

    Live Leadership Updates

    View All

    PMGC Holdings Inc. Expands Investment & M&A Efforts, Actively Seeking Acquisitions and Investments Through Strategic Sponsorship of TCA Venture Group

    NEWPORT BEACH, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (the "Company" or "PMGC," "our," or "we") (NASDAQ:ELAB), a diversified holding company, is proud to announce its annual sponsorship of TCA Venture Group's ("TCA") Orange County network for 2025. As a Southern California Network Sponsor, PMGC is actively pursuing investments and M&A opportunities to strengthen its portfolio while fostering local business growth and expanding its market presence. TCA Venture Group (formerly known as Tech Coast Angels) is one of the largest and most active angel investor networks in the United States. With a history spanning over 25 years, TCA has been instrumental in funding early-s

    2/27/25 8:00:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD

    Professor of Medicine at the University of California, Los Angeles (UCLA), where he serves as Director of the UCLA Metabolism Research Theme.Over 180 publications in the field of obesity & metabolism, along with multiple NIH-funded projects as Principal Investigator.Dr. Shirihai is a renowned researcher regularly invited as a keynote speaker at annual scientific conferences and has consulted for Johnson & Johnson, Bayer, AstraZeneca and Pfizer, among other healthcare companies. NEWPORT BEACH, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, announced the appointment of Orian Shirihai, MD, PhD, t

    7/30/24 9:00:26 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs

    NEWPORT BEACH, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, announced the formation of a new Scientific Advisory Board to support the advancement of EL-22, a first-in-class engineered probiotic approach, to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. "We are honored to be forming a Scientific Advisory Board with renowned members that possess deep and complementary knowledge in metabolic diseases, obesity, weight management, muscle preservation and physical function in addition to significant experience in clinical

    6/14/24 9:00:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Elevai Labs Inc.

    SC 13G - Elevai Labs Inc. (0001840563) (Subject)

    11/14/24 5:53:26 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Elevai Labs Inc.

    SC 13G - Elevai Labs Inc. (0001840563) (Subject)

    10/2/24 4:01:03 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Elevai Labs Inc.

    SC 13G - Elevai Labs Inc. (0001840563) (Subject)

    10/1/24 4:01:02 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAB
    Financials

    Live finance-specific insights

    View All

    PMGC Holdings Inc. Completes Acquisition of CNC Machining Company - AGA Precision Systems LLC

    Adds $1.39 Million in Cash-Flow-Positive Revenue from a CNC Machining, Mold Manufacturing, and Specialty Metals Operation Serving the Aerospace, Defense, and Industrial Markets.Adds to PMGC's U.S. Manufacturing Revenue Through a Second Bolt-On Acquisition Under Its Roll-Up Strategy, Bringing Estimated Total Annualized Revenue to Over $2.25 Million. NEWPORT BEACH, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) (the "Company," "PMGC" or "we"), a diversified public holding company, today announced that it has completed the acquisition of AGA Precision Systems LLC ("AGA"), a California-based CNC machining business that generated over $1.39 million in revenue in 2

    7/18/25 12:53:12 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMGC Holdings Inc. Completes Acquisition of Custom IT Packaging Company Pacific Sun Packaging with Over $2,000,000 in Combined Revenue for Fiscal Years 2023 and 2024

    Serves over 300 Commercial Clients including Data Centers, Technology Manufacturers and Information Technology (IT) Service Providers.Adds cash flow positive revenue, enhances PMGC's exposure to U.S. semiconductor and artificial intelligence ("AI") infrastructure growth, and marks the launch of its strategic acquisition program targeting U.S. businesses. NEWPORT BEACH, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) (the "Company," "PMGC," "we," or "us"), a diversified public holding company, today announced that it has completed the acquisition of Pacific Sun Packaging Inc. ("Pacific Sun") a specialized custom IT packaging company based in San Clemente, Califor

    7/10/25 8:30:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments

    Agreement adds two drug candidates to product pipeline consisting of (i) "EL-22", a clinical stage engineered probiotic expressing myostatin, and (ii) "EL-32", a preclinical engineered probiotic expressing dual myostatin & activin-A.Exclusive license covers global rights excluding South Korea.Clinical and preclinical data supports advancing EL-22, a novel investigational myostatin asset for the treatment of obesity for an investigational new drug "IND" application in 2025. EL-22 has demonstrated significant increase in body weight and restored muscle damage in preclinical mouse models, suggesting potential as a combination to glucagon-like peptide-1 "GLP-1" products to treat obesity. NEWPOR

    5/1/24 9:00:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care